5-lipoxygenase expression and tepoxalin-induced cell death in squamous cell carcinomas in cats

American Journal of Veterinary Research

Volumn 72, Issue 10, 2011, Pages 1369-1377

  Wakshlag, Joseph J ^a   Peters Kennedy, Jeanine ^a   Bushey, Jennifer J ^a   Loftus, John P ^a  

^a Cornell University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; LIPOCORTIN 5; LIPOXYGENASE INHIBITOR; TEPOXALIN;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CAT; CELL COMPARTMENTALIZATION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; MOUTH CANCER; NONHUMAN; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET RADIATION; WESTERN BLOTTING;

ANIMALS; ANNEXIN A5; APOPTOSIS; ARACHIDONATE 5-LIPOXYGENASE; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CAT DISEASES; CATS; CELL LINE, TUMOR; CELL PROLIFERATION; IMMUNOHISTOCHEMISTRY; LIPOXYGENASE INHIBITORS; MOUTH NEOPLASMS; PYRAZOLES; ULTRAVIOLET RAYS;

FELIDAE;

EID: 80053639290     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.72.10.1369     Document Type: Article

References (40)

1. Vail DM, Withrow SJ. Tumors of the skin and subcutaneous tissues. In: Withrow SJ, Vail DM, eds. Small animal clinical oncology.4th ed. St Louis: Saunders, 2007;375-401.
2. Head KW, Else RW, Dubielzieg RR. Tumors of the alimentary tract. In: Meuten DJ, ed. Tumors in domestic animals. 4th ed. Ames, Iowa: Blackwell Publishing, 2002;401-482.
3. Gil Z, Fiss DM. Contemporary management of head and neck tumors. Isr Med Assoc J 2009;11:296-300.
4. Pannone G, Bufo P, Grothey A, et al. Cyclooxygenase-2 expression in oral squamous cell carcinoma. Int J Immunopath Pharmacol 2004;17:273-282.
5. Pestili de Almeida EM, Piche C, Sirios J, et al. Expression of cyclo-oxygenase 2 in naturally occurring squamous cell carcinomas in dogs. J Histochem Cytochem 2001;49:867-875.
6. Mohammed SI, Khan KN, Sellers RS, et al. Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids 2004;70:479-483.
7. Hayes A, Scase J, Miller S, et al. COX-1 and COX-2 expression in feline oral squamous cell carcinoma. J Comp Pathol 2006;135:93-99.
8. DiBernardi L, Dore M, Davis JA, et al. Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment. Prostaglandins Leukot Essent Fatty Acids 2007;76:245-250.
9. Heller DA, Fan TM, deLorimier LP, et al. In vitro cyclooxygense-2 protein expression and enzymatic activity in neoplastic cells. J Vet Intern Med 2007;21:1048-1055.
10. Li N, Sood S, Wang S, et al. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventative effects of Zileuton and Celecoxib. Clin Cancer Res 2005;11:2089-2096.
11. Sun Z, Sood S, Li N, et al. Involvement of the 5-lipoxygenase/ leukotriene A4 hydrolase pathway in 7,12-DMBA-induced oral carcinogenesis in hamster cheek pouch and inhibition of carcinogenesis by its inhibitors. Carcinogenesis 2006;27:1902-1908.
12. Yang P, Sun Z, Chan D, et al. Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a DMBA-induced hamster cheek pouch model. Carcinogenesis 2008;29:2182-2189.
13. Schroeder CP, Yang P, Newman RA, et al. Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by Celecoxib. Curr Biol Ther 2004;9:847-852.
14. Porteder H, Matejka M, Ulrish W, et al. The cyclo-oxygenase and lipoxygenase pathways in human oral cancer tissue. J Maxillofac Surg 1984;12:145-147.
15. Metzger K, Angres G, Maier H, et al. Lipoxygenase products in human saliva: patients with oral cancer compared to controls. Free Radic Biol Med 1995;18:185-192.
16. Duffield Lillico AJ, Boyle JO, Zhou XK, et al. Levels of prostaglandin E metabolite and leukotriene E4 are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res 2009;2:322-329.
17. Furstenberger G, Krieg P, Muller-Decker K, et al. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis. Int J Cancer 2006;119:2247-2254.
18. O'Flaherty JT, Rogers LC, Pauma CM, et al. 5-oxo-ETE analogs and the proliferation of cancer cells. Biochim Biophys Acta 2005;1736:228-236.
19. Grant GE, Rokach J, Powell WS. 5-oxo-ETE and the OXE receptor. Prostaglandins Other Lipid Med 2009;89:98-104.
20. Rovati GE, Capra V. Cysteinyl-leukotriene receptors and cellular signals. Sci World J 2007;7:1375-1392.
21. Lascelles BDX, Court MH, Hardle EM, et al. Nonsteroidal anti-inflammatory drugs in cats: a review. Vet Anesth Analg 2007;34:228-250.
22. Wakshlag JJ, McNeill CJ, Antonyak MA, et al. Expression and activity of transglutaminase II in spontaneous tumors of dogs and cats. J Comp Pathol 2006;134:202-210.
23. Tannehill-Gregg S, Kergosein E, Rosol TJ. Feline head and neck squamous cell carcinoma cell line: characterization, production of parathyroid hormone-related protein and regulation by transforming growth factor-ß. In Vitro Cell Dev Biol 2001;37:676-683.
24. Wakshlag JJ, Antonyak MA, Boehm JE, et al. Effects of tissue transglutaminase on beta amyloid 1-42 induced apoptosis. Protein J 2006;25:83-94.
25. Antonyak MA, Miller AM, Jansen JM, et al. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem 2004;279:41461-41467.
26. Lin DT, Subbaramaiah K, Shah JP, et al. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002;24:792-799.
27. Fecker LF, Stockfleth E, Nidl I, et al. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal antiinflammatory drugs (NSAIDs). Br J Dermatol 2007;156:25-33.
28. Ding XZ, Talamonti MS, Bell RH, et al. A novel anti-pancreatic cancer agent, LY293111. Anticancer Drugs 2005;16:467-473.
29. Radmark O, Werz O, Steinhiler D, et al. 5-lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 2007;32:332-341.
30. Covey TM, Edes K, Fitzpatrick FA. Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor. Oncogene 2007;26:5784-5792.
31. Giannoni E, Fiaschi T, Ramponi G, et al. Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals. Oncogene 2009;28:2074-2086.
32. DeBoever S, Neirinkx E, Baert K, et al. Pharmacokinetics of tepoxalin and its active metabolite in broiler chickens. J Vet Pharmacol Therap 2008;12:97-100.
33. Argentieri DC, Ritchie DM, Ferro MP, et al. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism and potent anti-inflammatory activity and a favorable gastrointestinal profile. J Pharmacol Exp Ther 1994;271:1399-1408.
34. Knight EV, Keenan CM, Smith IL, et al. Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and Beagle dogs. Fundam Appl Toxicol 1996;33:38-48.
35. Cicero AFG, Laghi L. Activity and potential role of licofelone in the management of osteoarthritis. Clin Interv Aging 2007;2:73-79.
36. Sundaram S, Ghosh J. Expression of 5-oxo-ETE receptor in prostate cancer cells: critical role in survival. Biochem Biophys Res Comm 2006;339:93-98.
37. Hayashi T, Nishiyama K, Shirahama T. Inhibition of 5-lipoxygenase pathway suppresses the growth of bladder cancer cells. Int J Urol 2006;13:1086-1091.
38. Cianshi F, Cortesini C, Magnelli L, et al. Inhibition of 5-lipoxygenase by MK-886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol Cancer Ther 2006;5:2716-2726.
39. Fan XM, Tu SP, Lam SK, et al. Five-lipoxygenase activating protein inhibitor MK-886 induces apoptosis in gastric cancer through upregulation of p27kip1 and bax. J Gastroenterol Hepatol 2004;19:31-37.
40. Yoshida T, Shiraishi T, Horinaka M, et al. Lipoxygenase inhibitors induce death receptor5/Trail-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis. Cancer Sci 2006;98:1417-1423.